{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:45:15Z","timestamp":1767833115010,"version":"3.49.0"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Hematologic patients show lower responses to SARS-CoV-2 vaccines, but predictors of seroconversion are lacking. In this prospective cohort study, hematologic patients undergoing SARS-CoV-2 mRNA vaccination at a single center in Milan, Italy, were sampled for anti-Spike and anti-Nucleocapsid IgG titer at 5 \u00b1 1 weeks and at 3 months from the second vaccine dose. Patients (<jats:italic>N<\/jats:italic> = 393) received either BNT162b2 (Pfizer-BioNTech, 48%) or MRNA-1273 (Moderna, 52%), and 284 (72%) seroconverted and 100% persisted at 3 months. Non-response was higher in chronic lymphocytic leukemia (CLL) and lymphoma patients, and in those treated with small molecules and monoclonal antibodies. In myeloid neoplasms, lower responses were detected in patients with acute myeloid leukemia treated with venetoclax plus hypomethylating agents and in patients with myelofibrosis receiving ruxolitinib. Multivariable analysis showed that seroconversion was favorably associated with a diagnosis other than indolent lymphoma\/CLL [OR 8.5 (95% CI 4.1\u201317.6)], lack of B-cell-depleting therapy [OR 3.15 (1.7\u20135.9)], and IgG levels within the normal range [OR 2.2 (1.2\u20134.2)]. We developed a simple algorithm according to these 3 risk factors [(A) diagnosis of indolent lymphoma\/CLL, (B) B-cell-depleting treatment, and (C) low IgG] to predict non-response. IgG levels and treatment may be modifiable risk factors and should be considered for timing of vaccine administration.<\/jats:p>","DOI":"10.3389\/fimmu.2022.852158","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T06:32:35Z","timestamp":1652337155000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Seroconversion to mRNA SARS-CoV-2 Vaccines in Hematologic Patients"],"prefix":"10.3389","volume":"13","author":[{"given":"Bruno","family":"Fattizzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Bortolotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00f2","family":"Rampi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Cavallaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juri Alessandro","family":"Giannotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Bucelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramona","family":"Cassin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo Claudio","family":"Da Vi\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Galassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Noto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loredana","family":"Pettine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca Gaia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariarita","family":"Scium\u00e8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferruccio","family":"Ceriotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Consonni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilma","family":"Barcellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.07.012","article-title":"Antibody Response to SARS-CoV-2 Vaccines in Patients With Hematologic Malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00169-1","article-title":"Immunogenicity of the BNT162b2 COVID-19 mRNA Vaccine and Early Clinical Outcomes in Patients With Haematological Malignancies in Lithuania: A National Prospective Cohort Study","volume":"8","author":"Maneikis","year":"2021","journal-title":"Lancet Haematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41408-021-00534-z","article-title":"Weak Immunogenicity of SARS-CoV-2 Vaccine in Patients With Hematologic Malignancies","volume":"11","author":"Malard","year":"2021","journal-title":"Blood Cancer J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005094","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients With B-Cell non-Hodgkin Lymphoma","volume":"5","author":"Perry","year":"2021","journal-title":"Blood Adv"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.07.016","article-title":"Antibody and T Cell Immune Responses Following mRNA COVID-19 Vaccination in Patients With Cancer","volume":"39","author":"Ehmsen","year":"2021","journal-title":"Cancer Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.07.001","article-title":"Immune Responses to COVID-19 Vaccines in Patients With Cancer: Promising Results and a Note of Caution","volume":"39","author":"Griffiths","year":"2021","journal-title":"Cancer Cell"},{"key":"B7","unstructured":""},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2020.104480","article-title":"Brief Clinical Evaluation of Six High-Throughput SARS-CoV-2 IgG Antibody Assays","volume":"129","author":"Kohmer","year":"2020","journal-title":"J Clin Virol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-021-04169-7","article-title":"Sensitivity of Anti-SARS-CoV-2 Serological Assays in a High-Prevalence Setting","volume":"40","author":"M\u00fcller","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"B10","unstructured":"Establishment of the WHO International Standard and Reference Panel for Anti-SARSCoV-2 Antibody. WHO\/Bs\/2020.24032020"},{"key":"B11","unstructured":"First WHO International Standard Anti-SARS-CoV-2 Immunoglobulin (Human)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2021.07.005","article-title":"SARS-CoV-2 Anti-Spike Antibody Titres After Vaccination With BNT162b2 in Na\u00efve and Previously Infected Individuals","volume":"14","author":"Lombardi","year":"2021","journal-title":"J Infect Public Health"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01380-5","article-title":"Antibody Persistence 100 Days Following the Second Dose of BNT162b mRNA Covid19 Vaccine in Patients With Chronic Lymphocytic Leukemia","volume":"35","author":"Tadmor","year":"2021","journal-title":"Leukemia"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.852158\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T06:32:37Z","timestamp":1652337157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.852158\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":13,"alternative-id":["10.3389\/fimmu.2022.852158"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.852158","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]},"article-number":"852158"}}